Login to Your Account



Adaptimmune moves 2nd cancer immunotherapy into phase I trial

By Nuala Moran
Staff Writer

Monday, March 24, 2014
LONDON – Adaptimmune Ltd. has been awarded a £2.1 million (US$3.5 million) government grant enabling it to launch its second T-cell cancer immunotherapy product into clinical development in the UK, in the treatment of triple negative breast cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription